Progressive supranuclear palsy syndrome induced by clebopride.
We report on a patient who presented with a progressive supranuclear palsy (PSP) syndrome while receiving clebopride (CLB), a prokinetic drug with central antidopaminergic properties. The clinical and neurophysiological signs progressively disappeared after CLB withdrawal. To our knowledge, this is the first published PSP-like syndrome attributable to an antidopaminergic drug.
Campdelacreu
Jaume
J
Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Malalties del Sistema Nerviós (ICMSN), Hospital Clínic Universitari, Barcelona, Spain.
Kumru
Hatice
H
Tolosa
Eduard
E
Valls-Solé
Josep
J
Benabarre
Antoni
A
D000932:Antiemetics / Q000009:adverse effects*; D001549:Benzamides / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D013494:Supranuclear Palsy, Progressive / Q000139:chemically induced* / Q000175:diagnosis
D000932:Antiemetics; D001549:Benzamides; C014417:clebopride